aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• aTyr Pharma is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.18) per share.
• Shares of aTyr Pharma have recently traded at $5.03, with a market cap of approximately $447.23 million and significant institutional ownership at 61.72%.
• Recent analyst reports indicate a bullish outlook, with Wells Fargo raising their price target on aTyr Pharma stock to $25.00 and a general average target of $20.20.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

aTyr Pharma Stock Up 0.1%

Shares of ATYR traded up $0.01 during midday trading on Tuesday, reaching $5.03. The stock had a trading volume of 889,926 shares, compared to its average volume of 2,337,969. The company has a market cap of $447.23 million, a price-to-earnings ratio of -6.23 and a beta of 0.94. The company's fifty day simple moving average is $5.26 and its two-hundred day simple moving average is $4.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. aTyr Pharma has a 1-year low of $1.67 and a 1-year high of $7.29.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in aTyr Pharma stock. Millennium Management LLC increased its position in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 334.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,599,041 shares of the company's stock after buying an additional 1,231,052 shares during the quarter. Millennium Management LLC owned 1.80% of aTyr Pharma worth $4,829,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 61.72% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $20.20.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.